SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Alternext:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today it has executed with VGX Pharmaceuticals (“VGX”), a privately held DNA vaccine developer, an amended and restated merger agreement (“Amended Agreement”), which has been approved by both company’s boards of directors.
